Mulai
mooonshine199

KTRA 2x Phase two drugs data due soon.

Kintara Therapeutics, Inc. (NASDAQ:KTRA)  
mooonshine199  
NASDAQ:KTRA   Kintara Therapeutics, Inc.
Trend Analysis Fundamental Analysis
0
0
trendanalysis fundamental
100m shelf popped out of the blue, now in effect. Phase two data is due and looks to be positive. Cap is under 60m. Seems very undervalued here. The shelf is strange because the CEO has stated that they had enough cash to get through Q4/21, so why the offering now?
Pernyataan Penyangkalan

Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.